of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at